Published in Cancer Weekly, May 10th, 1999
One of the previous limitations of photodynamic therapy has been the lack of tumor selectivity of the photosensitizer. To overcome this problem, M.B. Vrouenraets and colleagues from the Free University of Amsterdam Hospital, The Netherlands, developed a protocol for coupling of meta-tetrahydroxyphenylchlorin to tumor-selective monoclonal antibodies (MAbs) ("Development of Meta-Tetrahydroxyphenylchlorin-Monoclonal Antibody Conjugates for Photoimmunotherapy," Cancer Research, April 1, 1999;59(7):1505-1513).
mTHPC is one of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.